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Recessive Mutations in DOCK6, Encoding the Guanidine
Nucleotide Exchange Factor DOCK6, Lead to Abnormal
Actin Cytoskeleton Organization and Adams-Oliver Syndrome
Ranad Shaheen,1 Eissa Faqeih,2 Asma Sunker,1 Heba Morsy,3 Tarfa Al-Sheddi,1 Hanan E. Shamseldin,1
Nouran Adly,1 Mais Hashem,1 and Fowzan S. Alkuraya.1,4,5,*
Adams-Oliver syndrome (AOS) is defined by the combination of aplasia cutis congenita (ACC) and terminal transverse limb defects
(TTLD). It is usually inherited as an autosomal-dominant trait, but autosomal-recessive inheritance has also been documented. In an
individual with autosomal-recessive AOS, we combined autozygome analysis with exome sequencing to identify a homozygous trun-
cating mutation in dedicator of cytokinesis 6 gene (DOCK6) which encodes an atypical guanidine exchange factor (GEF) known to acti-
vate two members of the Rho GTPase family: Cdc42 and Rac1. Another homozygous truncating mutation was identified upon targeted
sequencing of DOCK6 in an unrelated individual with AOS. Consistent with the established role of Cdc42 and Rac1 in the organization
of the actin cytoskeleton, we demonstrate a cellular phenotype typical of a defective actin cytoskeleton in patient cells. These findings,
combined with a Dock6 expression profile that is consistent with an AOS phenotype as well as the very recent demonstration of domi-
nant mutations of ARHGAP31 in AOS, establish Cdc42 and Rac1 as key molecules in the pathogenesis of AOS and suggest that other
regulators of these Rho GTPase proteins might be good candidates in the quest to define the genetic spectrum of this genetically hetero-
geneous condition.Adams-Oliver syndrome (AOS [MIM 100300]) is a multiple
congenital anomaly syndrome that is characterized by
aplasia cutis congenita (ACC) as well as terminal trans-
verse limb defects (TTLD) in addition to variable involve-
ment of the brain, eyes, and cardiovascular system.1–3
Original epidemiological data were consistent with a domi-
nant mode of inheritance due to presumed de novo (in
simplex cases) or familial (in multiplex families) muta-
tions. Horizontal transmission was initially suspected as
possible germline mosaicism, but multiple reports of recur-
rence in consanguineous unions made it likely that AOS
can also occur as an autosomal-recessive trait.3
The classic combination of ACC and TTLD and their
known association with vascular anomalies fueled specula-
tion that vascular disruption is a major pathogenic mech-
anism in AOS.2,4 However, recently dominant mutations
were found to cause AOS by virtue of Rac1 (MIM 602048)
and Cdc42 (MIM 116952) inactivation, which leads to
impaired actin cytoskeletal homeostasis.5 ARHGAP31 is
a GTPase-activating protein (GAP) that stimulates the
intrinsic GTPase activity of Rac1 and Cdc42 and thus
replaces their active GTP-bound form with the inactive
GDP-bound form.6 The two reported mutations in
ARHGAP31 (MIM 610911) were hypermorphic in nature,
causing sustained inactivation of Rac1 and Cdc42, which
are known to be of critical importance in regulating the
actin cytoskeleton.7 As a result, AOS appears to be a
member of a growing list of actin cytoskeletopathies that
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(NEM [MIM 609284, 256030, 161800, 609285, and
605355]) and Wiskott-Aldrich syndrome (WASF [MIM
605035, 605875, and 605068]).8–10
In our effort to molecularly characterize AOS in our
inbred population, where autosomal-recessive AOS is
seen more commonly,11 we have studied two unrelated
individuals who have this syndrome and were born to
consanguineous parents. We successfully combined auto-
zygome analysis with exome data in one of these two indi-
viduals to identify a loss-of-function mutation in DOCK6,
another modulator of Cdc42 and Rac1, and we then iden-
tified a second mutation in the other individual. Our data
on Dock6 expression and the cellular phenotype of fibro-
blasts of individual 1 further confirm the role of DOCK6
in AOS pathogenesis, which appears to converge with
that reported for ARHGAP31 in perturbation of the actin
cytoskeleton through inactivation of Cdc42 and Rac1.
Individual 1 is an 11-month-old girl born to first-cousin
Arab parents and who was referred for clinical genetics
evaluation. She has four normal siblings and a cousin
who is said to be similarly affected but who was unavail-
able for evaluation (Figure 1A). Pregnancy was uncompli-
cated. Abnormal hands and feet were noted at birth. At
11 months of age, she had severe and global develop-
mental delay, recurrent seizures, and poor vision. Physical
examination revealed microcephaly, large cutis aplasia of
the scalp, optic atrophy, and axial hypotonia with appen-
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Figure 1. Pedigrees of the Two AOS
Families Included in the Study and Clinical
Photographs of Individuals 1 and 2
(A) Family 1 pedigree.
(B) Clinical photographs of individual 1.
(C) Family 2 pedigree.
(D) Clinical photographs of individual 2.
Note the typical ACC and TTLD in both
individuals.of the fingers and toes bilaterally and an absence of distal
phalanges and nails (Figure 1B). Echocardiography was
normal. Brain CT demonstrated hydrocephalus with dila-
tation of the lateral ventricles and multiple small periven-
tricular and subependymal calcifications (Figure 1B).
X-rays of the hands and feet revealed absence of the distal
phalanges.
Individual 2 is a 3.5-year-old girl, the second child to
healthy first-cousin Arab parents (Figure 1C). She was
referred for evaluation of congenital deformity of the hands
and feet. Family history is negative. Therewas history of oli-
gohydramnios and decreased fetal movement during preg-
nancy. At birth, she was noted to have terminal-reduction
defects of her hands and feet and cutis aplasia of the scalp.
Her development appeared appropriate except for speech
delay. Her physical examination at 3.5 years revealed
microcephaly but normal height and weight. There was
an area of alopecia with an underlying scar in the scalp.
Finger and toe nails were either absent or severely hypo-
plastic, as were the distal phalanges, and her hands ap-
peared stubby with distorted creases (Figure 1D). X-rays of
the hands and feet revealed hypoplastic middle phalanges
and absent distal phalanges. Echocardiography, EEG, and
eye examination were all within normal limits.
The two individuals with AOS and their parents were en-
rolled in the study with an IRB-approved written informedThe American Journal of Human Geconsent (KFSHRC RAC#2080006).
Blood was collected in EDTA tubes
and Na-heparin tubes, and a small-
punch skinbiopsywas obtainedwhen-
ever possible. Autozygome analysis
was performed on individual 1 via
the Axiom SNP Platform (Affymetrix)
followed by autoSNPa genomewide
determination of runs of homozygos-
ity essentially as described before.12
Full-exome capture was performed
with the TruSeq Exome Enrichment
kit (Illumina) according to the manu-
facturer’s protocol. Samples were pre-
pared as an Illumina sequencing
library, and in the second step, the
sequencing libraries were enriched for
the desired target via the Illumina
Exome Enrichment protocol. The cap-
tured libraries were sequenced with Il-
lumina HiSeq 2000 Sequencer. Thereads were mapped against UCSC hg19 by BWA. The SNPs
and indels were detected by SAMTOOLS.
We have previously proposed the effectiveness of
combining autozygome data with next-generation se-
quencing.13 Indeed, using DNA from individual 1 alone,
we were able to apply his autozygome as a filter of the
resulting exome data; i.e., we only considered novel
coding-sequence variants that were detected within runs
of homozygosity (ten runs were identified for a total of
1303 genes). By applying this filter, we identified three
variants (two missense and one indel mutation; Table
S1, available online). We prioritized the 4 bp deletion
(c.1362_1365delAACT, p.Thr455Serfs*24; RefSeq accession
number NM_020812.2) in DOCK6 because it was the only
truncating mutation identified. Indeed, Sanger sequencing
confirmed this homozygous mutation in individual 1, and
her parents were found to be carriers (Figure 2). We then
fully sequenced DOCK6 in individual 2 and identified
a 1 bp duplication creating a stop codon (c.1245dupT,
p.Asp416*; RefSeq accession number NM_020812.2), and
segregation was confirmed within the family. This second
mutation represents an independent confirmation of the
involvement of DOCK6 disruption in the pathogenesis
of AOS.
In order to determine the developmental expression
pattern of Dock6, we performed WISH (whole-mountnetics 89, 328–333, August 12, 2011 329
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Figure 2. Identification of Two DOCK6 Muta-
tions in AOS
Upper panel: Diagram of DOCK6 (triangles indi-
cate the sites of the mutations). Middle panel:
Diagram of DOCK6 (note that both truncating
mutations are upstream of DHR-1 and DHR-2
domains). Bottom panel: Sequence chromato-
gram of the two mutations with the control
tracing for comparison (sequence differences are
underlined in red).in situ hybridization) on mouse embryos of various stages
of development. Expression of Dock6 at E9.5 was observed
in the growing edge of the limb buds and in the developing
heart (Figure 3A). At E10.5 the strongest expression was at
the edge of the limb buds, but the heart expressionwas also
maintained (Figure 3B). At E11.5 Dock6 mRNA was en-
riched in the apical ectodermal ridge of all four limbs
(Figure 3C). By E12.5 and E13.5, the expression of Dock6
assumed a more diffused pattern in the four limbs,
although the hind-limb, as in previous stages, was always
stronger than the fore-limb (Figures 3D and 3E), and at
E13.5 expression was clearly observed in the developing
digits (Figures 3F and 3G). Lack of comparable staining
with the corresponding sense probes confirmed specificity
of the observed signals (see Figures 3H and 3I for represen-
tative examples). We also carried out (q) RT-PCR on various
mouse adult tissues and found that although Dock6 is ex-
pressed in all tissues tested, there was significant Dock6
expression in the heart (Figure S1).
Because of the established role ofCdc42 andRac1 in actin
polymerization,14 we tried to gain insight into the cellular
phenotype of DOCK6 mutation by staining patient fibro-
blasts homozygous for the p.Thr455Serfs*24 mutation
and assessing cytoskeletal organization. A small percentage
of cells from individual 1 assumed a rounded phenotype
(three to four cells per high-power field [HPF], or 16%)
with ‘‘blebbing,’’ which we did not observe in control cells
(Figures 4A–4C). Compared to control cells, cells from indi-
vidual 1 also assumed an unusual elongated morphology
and lacked lamellopodia and lateral ruffles (Figures 4D
and 4E). The characteristics observed in cells from indi-
vidual 1 were similar to observations of F-Actin distribution
of Rac1-null fibroblast cells,15 and the rounded phenotype
was also similar to that recently observed forHeLa cells after
suppression of Cdc42 activity.16330 The American Journal of Human Genetics 89, 328–333, August 12, 2011Cdc42 and Rac1 are RhoGTPases, a family
of signaling proteins that, through induced
polymerization of actin filaments, play key
roles in a number of basic cellular processes,
such as proliferation, polarization, migra-
tion, adhesion, secretion, maintenance of
cell morphology, cytokinesis, apoptosis,
and phagocytosis.17,18 They function as
molecular switches that alternate between
an active GTP-bound form and inactive
GDP-bound form.19 This cycling in activitylevel is tightly regulated largely through the opposing
action of two classes of proteins: GEFs, which stimulate
the replacement of GDPwithGTP; andGAPs, which stimu-
late the intrinsic GTPase activity of Rho GTPase and the
consequent formation of the inactive GDP-bound form.19
GEFs are classically defined by their possession of Dbl
homology (DH) and pleckstrin homology (PH) domains,
which are required for exchange activity and membranous
localization, respectively.20,21 More recently, an atypical
family of GEFs, known as DOCKs, was identified in which
the protein lacks DH and PH but contains two Dock
homology region (DHR) domains, Dock homology region
1 (DHR1) and Dock homology region 2 (DHR2) which
carry out membranous localization and exchange activity,
respectively.22–24 DOCK proteins are further divided into
four groups on the basis of substrate specificity and
sequence alignment. DOCK6, along with DOCK7 and
DOCK8, belongs to group C, which increases the avail-
ability of the active GTP-bound form of both Cdc42 and
Rac1.25 Most available literature on DOCK-C proteins
concerns their action on the cytoskeletal reorganization
that is required for neurite outgrowth and dendrite forma-
tion in tissue culture experiments.26–28 However, available
data on germlinemutations in DOCK genes suggest a more
widespread physiological role. For example, mice with in-
activating Dock7 mutations have a generalized pigment
deficiency, and humans with inactivating DOCK8 muta-
tions have immunodeficiency.29,30
Similarly, DOCK6 was studied in the context of dendrite
and axon formation, but data on the phenotypic conse-
quences of germline mutation are lacking.25 In this study,
we show that recessive germline mutations of this gene
do indeed affect the actin cytoskeleton but primarily
cause ACC and TTLD rather than the expected neuronal
phenotype, although we note here that both individuals
Figure 3. WISH of Dock6 during Mouse Embryonic Development
(A) E9.5 mouse embryo showing expression in the growing edge of the limb bud.
(B) E10.5 mouse embryo showing expression in the growing edge of limb buds and heart.
(C) E11.5 mouse embryo showing expression in the apical ectodermal ridge of all four limbs (arrowheads and inset) as well as the
first-pharyngeal-arch-derived facial mesenchyme (triangles).
(D and E) E12.5 and 13.5 embryos showing the diffuse expression of Dock6 mRNA in the fore- and hind-limbs.
(F and G) Close-up view showing the expression in the limbs of an E13.5 embryo.
(H and I) Sense control for comparison with (F) and (G).displayedmicrocephaly and that individual 1 had evidence
of more severe brain involvement. Therefore, caution is
required in extrapolating data on the likely phenotype of
germline mutations from tissue culture experiments.
The twomutations we report are probably null in nature.
Even though NMD is excluded for at least one of the two
mutations (mutant transcript was readily identifiable on
RT-PCR in fibroblasts from individual 1; data not shown),
they are both predicted to encode mutant DOCK6 that
lacks its two fundamental domains. DHR2 was clearly
shown to be both necessary and sufficient for the GDP-
to-GTP exchange activity, and DHR1 was shown to be
responsible for the interaction with phosphatidylinositol-
3, 4, 5-triphosphate and hence the membranous localiza-
tion of DOCK proteins, but it was also shown to be neces-
sary for Rac-dependent cell elongation and cell migration
despite adequate Rac GTP loading.24,31 The latter observa-
tion suggests a model in which DHR1 is necessary for Rac
GTP loading, whereas DHR2 is necessary for the actual
Rac signaling.32
Consistent with the proposed null mechanism, our data
on the cellular phenotype are virtually identical to those
reported in the context of inactivation of Cdc42 and
Rac1 as a result of ARHGAP31 mutations; specifically, this
previous study reported a rounded cell appearance and
lack of lamellopodia formation.5 Therefore, a model
emerges in which impaired actin-cytoskeleton organiza-The Americtion by inactivation of Cdc42 and Rac1 is a final common
pathway in the pathogenesis of AOS, which can be caused
by either null mutations of the activating DOCK6 or hy-
permorphic mutations of the inactivating ARHGAP31.
Speculation on the link between Cdc42 and Rac1 inacti-
vation and the two key features of AOS can be informed by
previously published work. For example, Rac1 inactivation
in the developing limb buds in mice results in a TTLD
remarkably similar to those observed in humans.33,34
This is thought to be a combination of impaired apoptosis
of the presumptive interdigital spaces as well as improperly
oriented cellular migration. Correctly oriented cellular
migration was recently shown to be of critical importance
in proper limb bud formation.35 The explanation of the
ACC phenotype is less straightforward because it remains
unclear why it preferentially affects the vortex area of the
scalp. However, evidence shows that targeted inactivation
of TGF-b in mouse skin results in an ACC phenotype
with a location almost identical to that observed in AOS
patients.36 When combined with the recent revelation
that Cdc42 activation is necessary for the transduction of
TGF-b-induced mobilization of the actin cytoskeleton,37
a potential mechanistic insight into ACC pathogenesis in
AOS can be inferred.
In conclusion, our study shows the power of combining
exome and autozygome data in unraveling Mendelian
genetics by using simplex cases, a clear departure froman Journal of Human Genetics 89, 328–333, August 12, 2011 331
Figure 4. Patient and Control Fibroblast CellsWere Visualized by FluorescentMicroscopy for Phalloidin Staining of F-actin- andDAPI-
Stained Nuclei
F-actin staining is in red, and DAPI staining is in blue.
(A and B) Control fibroblasts (A) show the typical spindle appearance, whereas patient fibroblasts (B) show relatively high frequency of
rounded (solid arrowheads) and elongated (empty arrows heads) cells.
(C) A close-up view of one patient fibroblast with a rounded phenotype clearly indicates blebbing (arrow heads).
(D and E) The normal appearance of lamellopodia in control fibroblasts (D) is in sharp contrast to the ‘‘blunt’’ edges due to severe
deficiency of lamellopodia formation in patient fibroblasts (E).the classical requirement of large pedigrees. We also de-
monstrate that recessive and dominant AOS can be caused
by mutations in two modulators of the Cdc42 and Rac1
GTPase activity, which makes it possible that other modu-
lators of their signaling might be potential candidate genes
in this genetically heterogeneous condition.Supplemental Data
Supplemental Data include one figure and one table and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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